



SCIFINITI
PUBLISHING

Targeted Cancer Therapy Connect

ISSN: 3105-3629

Vol. 2, 2026



Open Access Peer-Reviewed Journal Specialized in
Targeted Cancer Therapy and Immunotherapy

Editor-in-Chief
Eyad Elkord, PhD

www.scifiniti.com

Targeted Cancer Therapy Connect

A Journal Specialized in Targeted Cancer Therapy and Immunotherapy

Volume: 2, 2026

Subject Categories

Targeted Cancer Therapy

Immunotherapy

Precision Oncology

Target Audience

Targeted Cancer Therapy Connect provides a platform for researchers, clinicians, and practitioners to share their findings, discuss challenges, and explore new frontiers in the fight against cancer through immunological approaches.



Eyad Elkord

Editor-in-Chief

Department of Biosciences and Bioinformatics
Xi'an Jiaotong-Liverpool University
Suzhou, China

Message from EiC

As we enter 2026 and launch a new volume of Targeted Cancer Therapy Connect, we reaffirm our commitment to serving as a trusted, peer-reviewed platform for researchers and clinicians to share high-quality advances in targeted cancer therapy, immunotherapy, and precision oncology. The journal welcomes innovative basic, translational, and clinical research that deepens understanding of tumour biology and tumour-immune interactions, and accelerates meaningful progress toward improved patient care. In 2026, we will place stronger emphasis on thematic/Special Issues and will be inviting researchers throughout the year to contribute and propose timely themes.

Aims and Scope

Targeted Cancer Therapy Connect is a peer-reviewed, open-access journal dedicated to advancing precision and targeted approaches in cancer treatment. The journal publishes innovative research that deepens understanding of the molecular and immunological mechanisms driving cancer progression and therapeutic response. Our goal is to accelerate the translation of scientific discoveries into effective, patient-centered cancer therapies.

Key Topics

Molecular Targets and Mechanisms – Discovery and validation of therapeutic targets; roles of oncogenes, tumor suppressors, signaling pathways, and the tumor microenvironment.

Targeted Therapeutics – Development of small-molecule inhibitors, monoclonal antibodies, antibody–drug conjugates (ADCs), peptide- and protein-based drugs, and next-generation modalities such as PROTACs.

Immunotherapy and Precision Oncology – Immune checkpoint inhibitors, bispecific antibodies, CAR-T and TCR-based therapies, vaccines, and biomarker-guided treatment strategies.

Drug Resistance and Combination Therapy – Mechanisms of resistance and rational combination regimens integrating targeted and immune-based agents.

Clinical Translation – Clinical trials of targeted agents, pharmacogenomics, predictive biomarkers, and case reports highlighting successful targeted interventions.

Technological and Methodological Advances – CRISPR, single-cell omics, proteomics, nanomedicine, and computational or AI-driven approaches for target discovery and drug development.

